IP Verse

Methods For The Treatment Of Her2 Amplified Cancer - EP3033079

The patent EP3033079 was granted to Pharmacyclics on Oct 31, 2018. The application was originally filed on Aug 12, 2014 under application number EP14835935A. The patent is currently recorded with a legal status of "Revoked".

EP3033079

PHARMACYCLICS
Application Number
EP14835935A
Filing Date
Aug 12, 2014
Status
Revoked
Jun 25, 2021
Grant Date
Oct 31, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 30, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2012219522
INTERNATIONAL-SEARCH-REPORTUS2013041014
OPPOSITIONEP2529622
SEARCHWO2010009342
SEARCHWO2015127234

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- CARMI, C. ET AL., "Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer", BIOCHEMICAL PHARMACOLOGY, (20121201), vol. 84, no. 11, pages 1388 - 1399, XP055090804
INTERNATIONAL-SEARCH-REPORT- ROBAK, T. ET AL., "Tyrosine kinase inhibitors as potential drugs for B- cell lymphoid malignancies and autoimmune disorders", EXPERT OPINION ON INVESTIGATIONAL DRUGS, (201207), vol. 21, no. 7, pages 921 - 947, XP008173387
INTERNATIONAL-SEARCH-REPORT- DY, G, K. ET AL., "Understanding, recognizing, and managing toxicities of targeted anticancer therapies", CA : A CANCER JOURNAL FOR CLINICIANS, (20130528), vol. 63, no. 4, pages 249 - 279, XP055315550
OPPOSITION- PAN Z. et al., "Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase", ChemMedChem, (20070100), vol. 2, no. 1, pages 58 - 61, XP055161655
OPPOSITION- CARMI C. et al., "Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer", BIOCHEMICAL PHARMACOLOGY, (20121201), vol. 84, no. 11, pages 1388 - 1399, XP055090804
OPPOSITION- LEPROULT E. et al., "Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors", J Med Chem., (20110300), vol. 10, no. 5, pages 1347 - 1355, XP055628121
SEARCH- NICOLE GRABINSKI ET AL, "Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells", INVESTIGATIONAL NEW DRUGS., US, (20140801), vol. 32, no. 6, doi:10.1007/s10637-014-0141-2, ISSN 0167-6997, pages 1096 - 1104, XP055222546 [XP] 1-11 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents